Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study

Key Takeaway: A recent pilot study has demonstrated that all 12 participants who received islet implants were able to discontinue the use of external insulin. This significant outcome highlights the potential of islet transplantation in managing diabetes. The study showcases the advancements in treatment options for patients, indicating a positive shift in diabetes care.
Price reaction · baseline $3.965 (2026-07-15T16:14:00.000Z) · hit during market hours · 1 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • All 12 recipients successfully off external insulin.
  • Pilot study shows promising results for islet implant.
  • Potential for transforming diabetes management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What was the outcome of the pilot study?

All 12 recipients were able to stop using external insulin.

What does the study indicate for diabetes management?

It suggests a significant advancement in treatment options for diabetes.

How many participants were involved in the study?

The study involved 12 participants.

What is the significance of islet implants?

Islet implants may transform diabetes management by reducing insulin dependency.

Last updated: Jul 15, 2026